Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

AURKA/KAP1 signaling in breast cancer metastasis

Award Number: R01CA311774
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/16/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2031

Group Awards By:

View Award Description

AURKA/KAP1 signaling in breast cancer metastasis - PROJECT SUMMARY/ABSTRACT Metastatic Breast Cancer (MBC) is an incurable disease, especially critical in a triple-negative (ER-/PR-/HER2) subtype of breast cancer (TNBC) due to its early emergence of metastases and lack of targeted therapy. Remarkable progress in diagnosing and treating early-stage breast cancer (BC) shows the critical need for early detection of cancers with high risk of dissemination to reduce mortality. Our team recently discovered a new marker of early cancer dissemination and metastasis - nuclear AURKA protein (N-AURKA). The nuclear AURKA expressing TNBC cells are highly invasive and disseminate early from oxygenated tumors via induction of unique gene expression signature enriched in cell migration/invasion (escape) genes and repression of adaptation genes (glycolysis, angiogenesis). We found that differential gene expression depends on the KAP1 - heterochromatin assembly factor. We show that N-AURKA recruits KAP1 to reduce chromatin accessibility. N- AURKA binding to KAP1 promotes its dimerization and sumoylation, which is needed for heterochromatin assembly and transcription repression. This phenomenon and its regulation by N-AURKA is novel and might be key to disseminating early-stage BCs. This application aims to determine KAP1-dependent transcriptome changes in N-AURKA cells leading to early oxygenated cancer dissemination. Our central hypothesis is that N- AURKA activates KAP1-dependent chromatin remodeling repressing adaptation genes that have promoters with KAP1 binding sites, thus inducing oxygenated cancer dissemination. Novel drugs designed by our group degrading N-AURKA will halt dissemination and, thus, metastasis. This hypothesis will be tested by executing the following specific aims: Aim 1: Determine the role of KAP1 in N-AURKA-driven transcriptome changes. We hypothesize that N-AURKA affects the expression of HIF1-dependent genes via the recruitment of KAP1. Aim 2: Determine the impact of KAP1 depletion on N-AURKA-driven oxygenated dissemination in TNBC mouse models. Aim 3. Determine the efficacy of PROTAC therapy specifically targeting Nuclear AURKA against early metastasis. The combination of innovative modeling approaches and new therapies will delineate the mechanisms of oxygenated dissemination affecting patients with early-stage and residual disease. Mechanistic understanding of how N-AURKA/KAP1 axis controls oxygenated cancer spread will majorly impact early metastatic cancer diagnostics and treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $443,359 )
2026	2026	WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION	886 CHESTNUT RIDGE ROAD	MORGANTOWN	WV	26505	MONONGALIA	USA	Cancer Biology Research	000	1	6/18/2026	NEW	$443,359
														Subtotal = $443,359

Grand Total All Awards = $443,359

Top

All Categories

About

Search

Reports

Data Submission

Award Information

AURKA/KAP1 signaling in breast cancer metastasis

Award Number: R01CA311774

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/16/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer